Consolidated statement of cash flows
Download(XLS, 36 KB)January 1 to December 31, € in millions | Note | 2022 | 2021 |
---|---|---|---|
Operating activities | |||
Net income | 2,117 | 2,819 | |
Adjustments to reconcile net income to cash and cash equivalents provided by operating activities |
|||
Depreciation and amortization | 18, 19, 20, 31 | 2,973 | 2,667 |
Change in deferred taxes | 11 | -115 | 84 |
Gain/loss on sale of fixed assets and of investments and divestitures | 2 | -116 | 42 |
Changes in assets and liabilities, net of amounts from businesses acquired or disposed of |
|||
Trade accounts and other receivables | 16 | 85 | 87 |
Inventories | 17 | -472 | -105 |
Other current and non-current assets | 18 | -360 | -320 |
Accounts receivable from / payable to related parties | -4 | -10 | |
Trade accounts payable, provisions and other short-term and long-term liabilities |
21, 22 | 140 | -154 |
Liabilities for income taxes | -50 | -32 | |
Net cash provided by operating activities | 4,198 | 5,078 | |
Investing activities | |||
Purchases of property, plant and equipment and capitalized development costs |
19 | -1,917 | -2,047 |
Proceeds from sales of property, plant and equipment | 140 | 30 | |
Acquisitions and investments and purchases of intangible assets |
2, 34 | -977 | -999 |
Proceeds from sale of investments and divestitures | 2 | 147 | 199 |
Net cash used in investing activities | -2,607 | -2,817 |
Consolidated statement of cash flows
Download(XLS, 35 KB)January 1 to December 31, € in millions | Note | 2022 | 2021 |
---|---|---|---|
Financing activities | |||
Proceeds from short-term debt | 23 | 698 | 3,279 |
Repayments of short-term debt | 23 | -2,655 | -688 |
Proceeds from long-term debt | 23 | 654 | 458 |
Repayments of long-term debt | 23 | -633 | -3,028 |
Repayments of lease liabilities | 31 | -975 | -880 |
Proceeds from the issuance of bonds | 24 | 3,044 | 2,714 |
Repayments of liabilities from bonds | 24 | -912 | -2,253 |
Proceeds from the Accounts Receivable Facility of Fresenius Medical Care |
23 | 95 | – |
Proceeds from the exercise of stock options | 36 | 20 | 38 |
Dividends paid | -890 | -1,068 | |
Change in noncontrolling interests, net | 27 | -50 | -24 |
Net cash used in financing activities | -1,604 | -1,452 | |
Effect of exchange rate changes on cash and cash equivalents | -2 | 118 | |
Net decrease/increase in cash and cash equivalents | -15 | 927 | |
Cash and cash equivalents at the beginning of the reporting period | 15 | 2,764 | 1,837 |
Cash and cash equivalents at the end of the reporting period | 15 | 2,749 | 2,764 |
Additional information on payments that are included in net cash provided by operating activities
Download(XLS, 35 KB)January 1 to December 31, € in millions | Note | 2022 | 2021 |
---|---|---|---|
Received interest | 137 | 94 | |
Paid interest | -610 | -517 | |
Income taxes paid | -850 | -750 | |
The following notes are an integral part of the consolidated financial statements. |